Unidade Local De Saude De Amadora Sintra E.P.E. — Clinical Trial Site

27 Registered trials

13 Currently recruiting

Organisation

Unidade Local De Saude De Amadora Sintra E.P.E.

Location

Amadora, Portugal

Identifier

ORG-100041447

Address

Itinerario Complementar 19, 2720-276, Portugal

Departments

5802: Oftalmologia
Autoimmune unit
Cardiology
Cardiology Department
Infectious Diseases
Internal Medicine
n/a
Neurology
Oftalmologia
Oncologia
Oncology
Oncology Department
Rheumatology
Serviço de Infeciologia
Serviço de Nefrologia
Serviço de Pneumologia
Systemic Immunomediated Diseases Unit
Unidade Integrada de Diabetes

Clinical trials at this site (27)

Search interface

Phase 3 trial of VMX-C001 vs usual pharmacological care in patients taking a FXa direct oral anticoagulant who require urgent surgery with o… Pending

2025-521632-12-00 Patients on Factor Xa inhibitor treatment needing an ur 5
A Clinical Trial to Compare the Effectiveness and Safety of RO7771950 in Combination with Trastuzumab and Capecitabine, Versus Tucatinib in … Recruiting

2025-524498-17-00 Pretreated Unresectable Locally Advanced or Metastatic 10 2026-05-08
A study to find out if BI 764198 helps adults and adolescents with a kidney condition called focal segmental glomerulosclerosis (FSGS) Recruiting

2025-522191-86-00 Focal segmental glomerulosclerosis 5 2026-04-02
COLCOT-T2D Recruiting

2024-516646-19-00 Type 2 diabetic patients with no prior cardiovascular ( 5 2025-08-15
Clinical trial that compares MK-2870 with or without pembrolizumab to chemotherapy in people with breast cancer that cannot be surgically re… Recruiting

2023-504918-29-00 Hormone receptor positive breast cancer 5 2024-08-22
A study of different investigational treatments in people with the interstitial lung disease that accompanies scleroderma (CONQUEST) Recruiting

2023-507129-40-00 interstitial lung disease secondary to systemic scleros 4 2024-08-06
Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE (POETYK SLE-2) Recruiting

2022-500700-22-00 Active Systemic Lupus Erythematosus (SLE) 5 2023-05-25
EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure… Recruiting

2025-521188-11-00 Type 2 diabetes 5 2025-10-15
A PHASE 2 STUDY TO RESEARCH THE SAFETY AND EFFICACY OF TRASTUZUMAB DERUXTECAN VERSUS CDK4/6I PLUS ENDOCRINE THERAPY IN ADVANCED BREAST CANCE… Recruiting

2024-512360-55-00 Unresectable locally recurrent or metastatic hormone re 4 2025-06-30
An Ophthalmic Safety Study of New Investigational Drug in Breast Cancer Patients Recruiting

2024-512161-14-00 Breast Cancer 3 2025-01-14
Long-term safety and tolerability of cenerimod in adults with systemic lupus erythematosus (OPUS OLE) Recruiting

2024-514354-67-00 Systemic lupus erythematosus 5 2024-11-01
Clinical trial of MK-2870 in combination with pembrolizumab in people who have had surgery to treat triple negative breast cancer Recruiting

2023-504962-52-00 Triple negative breast cancer. 5 2024-07-10
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Can… Recruiting

2023-507914-28-00 Platinum-resistant, high-grade serous ovarian cancer (O 10 2024-06-19
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting

2023-504031-41-00 ER+/HER2- Early Breast Cancer 5 2024-03-25
A research study to evaluate the efficacy and safety of cenerimod in subjects suffering from systemic lupus erythematosus Ended

2024-515871-37-00 Moderate to severe systemic lupus erythematosus 5 2024-10-24
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended

2022-501024-20-00 ER+/HER2- Early Breast Cancer 5 2023-07-25
OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended

2022-501608-85-00 Cardiovascular disease (atherosclerotic cardiovascular 5 2023-05-09
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic … Ended

2023-509825-38-00 Metastatic Non–Small Cell Lung Cancer 5 2022-12-01
Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer after FDG-PET response-adapted strategy. The PHERGain study Ended

2023-509923-42-00 HER2- positive breast cancer 4 2017-07-06
Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated Ended

2024-512505-66-00 HIV-1 Infection 10 2025-03-03
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events and Disease Activity in Adult Participants With Migraine… Ended

2022-501172-25-00 Chronic and Episodic Migraine 5 2024-01-17
A study to test asundexian for preventing a stroke caused by a clot in participants after an acute ischemic stroke or after a high-risk tran… Ended

2023-503793-20-00 Prevention of ischemic stroke in patients post acute no 5 2023-01-18
Cohort study of human mpox virus disease Ended

2022-501132-42-00 Monkeypox virus disease 6 2022-08-02
A randomized, 2-arm, open-label, phase II study of abemaciclib combined with endocrine therapy (letrozole or fulvestrant) with or without a … Ended

2023-509591-42-00 HR-positive/HER2-negative breast cancer 4 2021-05-04